Journal of International Medical Research · 2009 · 21 citations · 19 references
MedicineOncologyPathologyMolecular PathologyNeoplasiaTumor PathologyCancer BiomarkersCancer DetectionFluid AnalysisTumor AntigensTumor MarkersTumor-associated AntigensAscitic Fluid AnalysisCancer Antigen 125Cancer Antigen 19-9Circulating Tumor BiomarkersMalignant AscitesPearson Correlation CoefficientSerum BiomarkersSerum Tumor Markers
Correlations between tumour markers in ascitic fluid and serum were investigated to determine whether ascitic fluid analysis had any diagnostic advantage over serum in 91 adults with ascites (55 malign; 36 benign). Serum and ascitic fluid were analysed for carcinoembryonic antigen (CEA), cancer antigen (CA) 125, CA19.9, CA72.4, CA15.3, alpha-fetoprotein (AFP) and cytokeratin-19 fragment (CYFRA). The tumour markers were skewed between the groups so were logarithmically transformed. Correlations between serum and ascitic fluid were tested using Pearson's correlation coefficient. Serum and ascitic fluid levels of CEA, CA125, CYFRA and AFP in the malign group were statistically different and CEA, CA19.9, CA5.3, CYFRA and AFP were statistically different in the benign group. For both groups, all tumour markers were highly correlated in serum and ascitic fluid, with the exception of CYFRA in the malign group. These results indicate that, where malignant ascites is suspected, analysing tumour markers in ascitic fluid does not have any advantage over serum analysis.
19
An Introduction to Medical Statistics.
Journal of the American Medical Association · 1931 · 2.1K citations
Yong Xu, Shaihong Zhu · Hepatogastroenterology · 2011 · 1.3K citations
Bruce A. Runyon · New England Journal of Medicine · 1994 · 402 citations